Sandoz pulls injectable methotrexate due to particulate matter

05/22/2013 | MedPage Today (free registration)

Sandoz recalled two lots of its methotrexate sodium USP, 25 mg/mL, 40 mL vial injectable drug, which is indicated for rheumatoid arthritis, severe psoriasis and neoplastic diseases. The drugmaker found particulate matter in vials of lots CL0996 and CJ4948 while performing a routine quality inspection. Parenteral injection of the recalled products "can lead to microembolisation in areas where the particles lodge," the FDA warned in a press release.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC